MERTK and neoplasm: Similarly, in the GL261 model, no differences were observed in OS or in tumor volume in Mertk-/-V2Tyro3-/-V2 mice following the DC vaccination strategy that conferred significant anti-tumor resistance to Mertk-/-V1 mice (Figure 6G and H).